High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.

The short version

This network meta-analysis pooled 40 randomized controlled trials with 6,616 migraine sufferers to answer a question few doctors are asked but many patients wonder: can fish-oil omega-3s genuinely compete with prescription drugs for preventing migraines? Migraine affects roughly one in ten people worldwide, and standard preventive medications work for only 40–50% of those who try them, often with side effects that drive people to quit. Network meta-analysis is a technique that connects every studied treatment through shared comparison arms — here, 40 trials from the United States, Iran, Brazil, France, Norway and beyond, covering omega-3 supplements (EPA and DHA, the two main long-chain omega-3 fatty acids) alongside FDA-approved preventives like topiramate, valproate, amitriptyline, and propranolol. Participants averaged 35 years old and 79% were women, matching migraine's real-world demographics. Treatments ran 8 to 16 weeks, with migraine frequency and dropout rates as the primary measuring sticks. High-dose EPA/DHA ranked first in the entire network on every efficacy measure. It cut migraine frequency more than any drug (standardized mean difference −1.36 versus placebo, 95% CI −2.32 to −0.39 — a large effect) and reduced attack severity even more decisively (SMD −2.23, 95% CI −3.17 to −1.30). Just as important, people stuck with it: dropout was identical to placebo (odds ratio 1.00), while every prescription preventive in the network lost more patients along the way. The trade-off for honesty: the omega-3 trials were smaller than the drug trials, and the confidence intervals around these estimates are wide. This analysis moves high-dose omega-3 supplementation from "can't hurt" folk advice to a first-line candidate with top-of-network evidence, most relevant where preventive-drug side effects have been limiting. The benefit tracked the high-dose regimens, not the small amounts found in a typical daily fish-oil capsule.

Key findings

• This network meta-analysis pooled 40 randomized trials (6,616 participants) comparing omega-3 fatty acid supplements against every standard migraine-prevention drug on a single statistical playing field.
• High-dose EPA/DHA (the two main omega-3 fatty acids in fish oil) ranked first of all interventions for reducing both migraine frequency (SMD -1.36 vs placebo) and severity (SMD -2.23).
• People were no more likely to quit high-dose omega-3 than placebo - a tolerability profile no prescription preventive in the analysis matched.
• The dose was decisive: benefits tracked high-dose regimens, not the smaller amounts in a typical daily fish-oil capsule.
• The authors conclude high-dose EPA/DHA can be considered a first-choice migraine preventive, while noting the omega-3 trials were smaller than drug trials and the confidence intervals wide.

Common questions